Merck's Vytorin Study Epitomizes Inherent Risks Of Major Clinical Trials

But, as Merck has taught us with IMPROVE-IT, CVOTs are risky and success is not a given.

Source: Forbes.com Healthcare News - December 16, 2015 Category: Pharmaceuticals Authors: John LaMattina Source Type: news